The offering is a distressed capital raise at a deep discount to the stock's already-low price, with proceeds insufficient to fund operations beyond the near term given the company's burn rate and no product revenue. Monitor the Nasdaq compliance deadline (Jan 11, 2027) and the company's ability to secure additional non-dilutive funding or a partnership to extend the cash runway.
Executive Summary
Actuate Therapeutics filed Pre-Effective Amendment No. 2 to its S-1 registration statement for a public offering of 40,000,000 shares of common stock and 20,000,000 purchase warrants, plus up to 40,000,000 pre-funded warrants, at an assumed combined price of $1.00 per two shares and one warrant. The company is a clinical-stage biopharmaceutical firm developing elraglusib, a GSK-3 inhibitor for difficult-to-treat cancers, and has no product revenue, with cash of $4.4M as of June 30, 2026, and a going concern risk. The offering is highly dilutive (immediate dilution of ~$0.20/share) and the stock trades at $0.50, below the Nasdaq Global Market's $50M MVLS requirement, with a compliance deadline of January 11, 2027.
Key Facts
- Offering: 40M shares + 20M purchase warrants (5-year term, exercise price TBD) + up to 40M pre-funded warrants ($0.0001 exercise price).
- Assumed combined offering price: $1.00 per two shares + one warrant; stock closed at $0.50 on Oct 15, 2026.
- Net proceeds estimated at ~$19.3M (after discounts and expenses), used for working capital and general corporate purposes.
- Cash and cash equivalents of $4,425,841 as of June 30, 2026; working capital of $942,745.
- Company has no product revenue and expects to continue incurring significant operating losses.
- Immediate dilution of ~$0.20 per share for new investors (assumed offering price $0.50 vs. adjusted net tangible book value of $0.30).
- Nasdaq Global Market non-compliance: MVLS below $50M; must regain compliance by Jan 11, 2027 or face delisting.
- Top shareholders (Bios and Kairos entities, ~50% combined) agreed to 2-year lock-up; other officers/directors have 120-day lock-up.
- Underwriter (Newbridge Securities) receives 7% discount, expense reimbursement up to $125K, and warrants for 3.5% of shares sold.
- Company has a Committed Equity Facility with B. Riley (3.36M shares remaining) and an ATM Facility ($98.7M remaining capacity).
Financial Impact
Net proceeds of ~$19.3M from the offering, with immediate dilution of ~$0.20/share for new investors. Cash position of $4.4M as of June 30, 2026.
Risk Factors
- Nasdaq delisting risk: MVLS below $50M; failure to regain compliance by Jan 11, 2027 could lead to OTC trading and reduced liquidity.
- Going concern risk: Cash of $4.4M and no product revenue; the offering proceeds (~$19.3M) may not be sufficient to fund operations through key clinical milestones.
- Extreme dilution: The offering adds 40M shares (166% of current 24M outstanding) plus warrants for another 20M+ shares, severely diluting existing holders.
- Clinical risk: Elraglusib is still in clinical development; no approved products; Phase 1/2 oral tablet study requires additional funding.
- Insider selling risk: Despite lock-ups, the large shareholder base (Bios/Kairos at ~50%) could seek liquidity after the 2-year lock-up expires.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001683168-26-007941 |
| Document: actuate_s1a.htm | 0001683168-26-007941 |
| Document: actuate_ex0410.htm | 0001683168-26-007941 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | S-1/A | $0.5990 $0.5279 | ▲ +11.87% | ▲ +11.72% | $0.4750 (+20.70%) |
Oct 14, 2026 12d ago | S-1/A | $0.4342 $0.5622 | ▼ −29.48% | ▼ −29.03% | $0.4750 (−9.40%) |
Oct 6, 2026 20d ago | S-1 | $0.7240 $0.4340 | ▲ +40.06% | ▲ +39.07% | $0.4750 (+34.39%) |
Aug 12, 2026 10w ago | Institutional Cluster | $0.9699 $1.06 | ▼ −9.29% | ▼ −9.73% | $0.4750 (+51.03%) |
Jun 9, 2026 19w ago | Press Release | $2.01 $2.05 | ▲ +1.99% | ▼ −0.42% | $0.4750 (−76.37%) |
May 11, 2026 24w ago | 8-K | $2.89 $2.43 | ▼ −15.92% | ▼ −15.99% | $0.4750 (−83.56%) |
May 6, 2026 24w ago | DEFA14A | $2.99 $2.89 | ▼ −3.34% | ▼ −4.48% | $0.4750 (−84.11%) |
May 6, 2026 24w ago | 8-K | $2.99 $2.89 | ▼ −3.34% | ▼ −4.48% | $0.4750 (−84.11%) |
Apr 14, 2026 27w ago | Press Release | $2.08 $2.27 | ▲ +8.89% | ▲ +7.50% | $0.4750 (−77.16%) |
Mar 9, 2026 33w ago | Press Release | $2.95 $2.68 | ▼ −9.00% | ▼ −7.64% | $0.4750 (−83.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers